A new study has unveiled that GLP-1 receptor agonists, a class of medications primarily used for diabetes and obesity, may also play a significant role in reducing the risk of addiction. The study, published today in the BMJ, highlights that drugs such as semaglutide (Ozempic), liraglutide, and tirzepatide (Wegovy) could potentially help individuals struggling with substance use disorders.
These medications mimic a hormone that regulates blood sugar and appetite, and their potential in addiction treatment has sparked interest over the past decade. Notably, some patients prescribed these drugs for diabetes or weight loss have reported a decrease in alcohol consumption and smoking.
Study Insights: Reduced Risk and Improved Outcomes
The study analyzed electronic health records from over 600,000 veterans with diabetes treated through the United States Department of Veterans Affairs. It revealed that starting a GLP-1 drug was linked to a 14% overall reduced risk of developing new substance use disorders, including alcohol, cannabis, cocaine, nicotine, and opioids. Furthermore, for individuals with an existing substance use disorder, GLP-1 usage was associated with a 26% reduction in substance-related hospital admissions.
Methodology and Comparisons
Researchers employed a method known as “target trial emulation,” which structures an observational study to closely resemble a randomized controlled trial. Participants newly prescribed a GLP-1 were compared with those started on SGLT2 inhibitors, another class of diabetes medication. The study sought to answer whether GLP-1 drugs could prevent the onset of addiction and reduce serious harms among those already diagnosed with a substance use disorder.
While the study’s design is among the best for observational data, it cannot definitively prove causation. However, the results were promising. Among individuals without a prior substance use disorder, those on GLP-1 drugs showed a reduced likelihood of developing one across various substances:
- Alcohol: 18% lower risk
- Cannabis: 14% lower risk
- Cocaine: 20% lower risk
- Nicotine: 20% lower risk
- Opioids: 25% lower risk
These findings equate to approximately 1–6 fewer cases per 1,000 people over three years.
Impact on Existing Substance Use Disorders
For those already diagnosed with a substance use disorder, GLP-1 drugs were linked to improved outcomes:
- 31% fewer emergency department visits
- 26% fewer hospital admissions
- 39% reduction in overdoses
- 25% reduction in suicidal thoughts or attempts
- 50% fewer deaths
This translated to roughly 1–10 fewer events per 1,000 people over three years.
The consistency of these patterns across various substances and outcomes strengthens the case for further investigation. However, ongoing randomized trials will be crucial to confirm whether GLP-1 drugs are the direct cause of these benefits.
Limitations and Considerations
Despite the promising results, the study’s cohort was predominantly male (90%) with an average age of 65, raising questions about the applicability of findings to women, younger individuals, or those without type 2 diabetes. The group also presented significant health complexities, with a high prevalence of smoking, high cholesterol, and mental health conditions such as PTSD, depression, and anxiety.
The study did not account for whether participants were receiving treatment for their substance use disorder, which could influence outcomes. This limitation underscores the necessity for further research to explore the broader applicability of GLP-1 drugs in addiction treatment.
Broader Implications and Future Directions
Perhaps the most critical takeaway from this study is not solely about GLP-1 drugs. It highlights the treatability of substance use disorders, emphasizing the availability of effective, evidence-based medications like naltrexone, acamprosate, methadone, and buprenorphine, alongside psychological therapies.
Despite their efficacy, only a small fraction of individuals with substance use disorders receive these treatments, largely due to stigma and societal perceptions of addiction as a moral failing rather than a health condition. This research on GLP-1s is encouraging, but it also serves as a reminder of the need to address these barriers and improve access to existing treatments.
As the medical community awaits the results of ongoing randomized trials, the potential of GLP-1 drugs in addiction treatment remains a promising area of exploration. The findings could pave the way for new therapeutic approaches, offering hope to millions affected by substance use disorders.
